All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
One of the most prominent toxicities associated with CAR-T immunotherapies is cytokine-release syndrome (CRS), which can be fatal if not properly identified and managed. Creative Biolabs offers the most extensive portfolio of CRS immunoassay platforms and services for measuring CRS-associated inflammatory cytokines and evaluating CRS process. Whether you need qualitative or quantitative results, have limited sample, require single or multianalyte analysis, you will be able to find an optimal solution from Creative Biolabs.
Cytokine release syndrome (CRS) is a collection of acute systemic inflammatory syndromes associated with certain types of immunotherapy (especially immunotherapy involving T cells). The syndrome is characterized by fever and multiple organ dysfunction when immune cells are activated and release large amounts of cytokines into the body. Creative Biolabs gave a comprehensive overview of CRS, mainly providing CRS management solutions for the following diseases:
Creative Biolabs provide one-stop assay portfolio for CRS cytokine release assay, cytotoxicity analysis in vitro and in vivo. Multiple methods are available for cytokine release assay, including Intracellular Cytokine Staining (ICS), ELISPOT and ELISA / CBA. Multiple combination of cytokine panels is also ready for cytokine release assay. In addition, we also provide comprehensive in vitro and in vivo CRS research models supporting CRS assay, such as in vitro human PBMCs and NHP PBMCs models, PBMC-engrafted humanized in vivo mouse model, and donor-dependent in vivo mouse model.
CRS Research Models includes In Vitro CRS Models and In Vivo CRS Models
The occurrence and evolution of CRS involve several events, including early CAR-T cell expansion and extended immune response, early identification and diagnosis of CRS, determinant of CRS, toxicity assessment of CRS, and specific treatment development.
To thoroughly investigate mechanism of action of your agent, we have developed several novel platforms for fully understand the therapeutic effect, immunogenicity, and candidate biomarkers induced by your agent in vitro and in vivo.
If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION